Mobile Site ›

Risk Stratification in Chronic Lymphocytic Leukemia

The Role of the Clinical Laboratory

Risk Assessment

Slide 35

November 2008

To summarize, when a patient with potential CLL comes to the laboratory, think of it as a three-step process.

First of all, the diagnosis is made based on the peripheral blood CBC and differential count as well as the immunophenotype.

Second, risk assessment based on clinical, hematology, immunophenotyping and genetic and molecular studies.

Finally, assessing outcome post-therapy based on immunophenotype, potential immunohistochemistry and certainly clinical and MRI staging.

Today we have tried to cover this middle segment, or risk assessment.

Risk Assessment


Jump to section: